Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mannan-MUC1 fusion protein
- Development stage
- Unknown
- Lead developer
- Immutep
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intradermal, Intraperitoneal, Intravenous, Subcutaneous, (also Via Dendritic Cell Infusion/ex Vivo Pulsing)
01
Overview
Mannan-MUC1 fusion protein is an experimental cancer immunotherapy comprised of the human tumor-associated antigen MUC1 covalently linked to the yeast cell-wall polysaccharide mannan. This fusion aims to enhance the immunogenicity of MUC1, which is overexpressed and abnormally glycosylated in many epithelial cancers, especially breast, colon, stomach, rectum, and ovarian cancers. Preclinical studies and early-phase trials have shown that mannan-MUC1 induces strong T cell-mediated and humoral immune responses by targeting antigen-presenting cells and stimulating cytotoxic T lymphocytes, with evidence of tumor stabilization in some patients. It has been tested both as a direct vaccine and in autologous dendritic cells pulsed with the fusion protein, with clinical trials showing robust cellular immune responses and a favorable safety profile[1][2][3][4][9].
- Other names
- mannan-MUC1mannan-MUC-1mannan-MUC 1MFPmannan-MUC1-pulsed dendritic cell vaccinemannan-MUC-1-pulsed dendritic cell vaccinemannan-MUC 1-pulsed dendritic cell vaccine
02
Targets
MRC1 (Mannose Receptor C-type 1)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on mannan-MUC1 fusion protein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mannan-MUC1 fusion protein.